Search Results
Your search for all items matches 33996 pages
Showing 551 - 600Preserving Reproductive Health for Patients With Cancer: Insights From an Oncofertility Patient Navigator
Advancements in cancer therapies have led to increased survival rates, but this progress has come with a cost: many life-saving treatments may impair fertility, leaving patients and cancer survivors grappling with the potential loss of their reproductive abilities. Oncofertility, a field that...
Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....
Are Eligible Breast Cancer Survivors Receiving Genetic Testing?
Researchers have found that many eligible breast cancer survivors may not be receiving genetic counseling and testing, according to a recent study published by Katz et al in the Journal of Clinical Oncology. Background A growing proportion of cancer treatment and survivorship care relies on...
Uncovering the Genetic Risk of Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...
Overcoming the Disparity in Cancer Incidence and Mortality Rates Among Alaska Native Individuals
Research has consistently shown that Native American and Alaska Native individuals are among the most underserved minority populations in the United States and are disproportionately affected by cancer. The results from a 50-year report by the Alaska Native Tribal Health Consortium’s Alaska Native...
Immunotherapy-Induced Multiorgan Immune-Related Adverse Events: Co-occurrence Patterns and Prognostic Implications
The results of a retrospective multicohort study, reported in The Lancet Oncology by Wan et al, suggested that the identification of the immune-related adverse event cluster to which a patient belongs may aid in prognosticating response to immunotherapy. “These insights can be leveraged to counsel...
Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma
In a single-institution phase II trial reported in JAMA Oncology, Pinnix et al found that response-adapted radiation therapy featuring ultra–low-dose radiation therapy was a successful strategy in patients with indolent B-cell lymphoma of the ocular adnexa. As stated by the investigators:...
Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer
Heather McArthur, MD, MPH, talks about immunotherapy for high-risk, early-stage breast cancer. Dr. McArthur is Associate Professor in the Department of Internal Medicine and Clinical Director of the Breast Cancer Program at Simmons Cancer Center at UT Southwestern Medical Center, Houston. She...
Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational...
New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer
The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently being validated in the I-SPY2.2 trial, according to Laura van ’t Veer, PhD, Professor of Laboratory...
Testosterone Therapy May Protect Against Breast Cancer in Transmasculine Patients
Gender-affirming testosterone therapy may have a potential protective benefit in transmasculine patients at risk of breast cancer, according to a recent study published by Heng et al in Breast Cancer Research. Background To treat their gender dysphoria, some transmasculine patients undergo...
Donor Socioeconomic Status May Influence Outcomes in Hematopoietic Cell Transplantation
Investigators have demonstrated that the socioeconomic status of cell donors may impact the health outcomes of patients with hematologic malignancies who undergo hematopoietic cell transplantation, according to a recent study published by Turcotte et al in PNAS. Study Methods and Results In the...
How Does Endometriosis Typology Influence Ovarian Cancer Risk?
In a Utah population–based cohort study reported in JAMA Network Open, Barnard et al found that women with ovarian endometriomas and/or deep-infiltrating endometriosis had a markedly increased risk of developing ovarian cancer. Those with such severe subtypes may represent an important population...
EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors
In a Chinese phase I trial reported in The Lancet Oncology, Ma et al found that BL-B01D1—a first-in-class EGFR-HER3 bispecific antibody-drug conjugate—was active in previously treated patients with locally advanced or metastatic solid tumors. Study Details In the multicenter trial, 195 patients...
Neha Vapiwala, MD, FACR, FASTRO, FASCO, Voted President-Elect of ASTRO
The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors: Neha Vapiwala, MD, FACR, FASTRO, FASCO, President-Elect Jean Wright, MD, FASTRO, Clinical Affairs and Quality Council Vice Chair Andrea Ng, MD, MPH, FASTRO,...
New Imaging Guidelines for Head and Neck Cancers Published
Researchers have developed new imaging guidelines, representing a major shift in the management of patients with head and neck cancers, according to a study published by Henson et al in The Lancet Oncology. The guidelines may lay the foundation for these patients to be treated with tailored...
Electronic Health Record–Based Prompt May Help Reduce Breast Cancer Overtreatment
Researchers have developed a novel prompt, embedded in electronic health records, to flag older patients with early-stage breast cancer who may be at risk of unnecessary sentinel lymph node biopsy, according to a recent study published by Carleton et al in JAMA Surgery. Background “In breast...
LBCL: CD22-Directed CAR T-Cell Therapy After Disease Progression on CD19-Directed CAR T-Cell Therapy
In a single-center phase I trial reported in The Lancet, Frank et al found that CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) showed activity in patients with large B-cell lymphoma (LBCL) whose disease progressed on CD19-directed CAR T-cell therapy (CAR19). CD22 is a nearly...
Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases
In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicenter, European TRANSMET trial, presented at the 2024 ASCO Annual Meeting.1 The combined approach led...
A Role for Avelumab in Triple-Negative Breast Cancer?
In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly improve overall survival and risk of distant disease–free survival events. The results from the...
Recurrent Cervical Cancer: Tisotumab Vedotin in Second- or Third-Line Therapy
As reported in The New England Journal of Medicine by Ignace Vergote, MD, PhD, and colleagues, interim analysis of the phase III innovaTV 301 trial has shown improved overall survival and other efficacy outcomes with the antibody-drug conjugate tisotumab vedotin-tftv vs investigator’s choice of...
New Study Demonstrates Safe, Successful Pregnancy May Be Possible Following Allo-HCT
Female patients may become pregnant and give birth to healthy children despite treatment-related fertility challenges following allogeneic hematopoietic cell transplantation (allo-HCT), according to a recent study published by Sockel et al in Blood. The findings highlighted the need for increased...
Hormone-Modulating Therapy May Be Linked to Lower Dementia Risk in Patients With Breast Cancer
Hormone-modulating therapy used to treat patients with breast cancer may be associated with a 7% lower risk of developing Alzheimer’s disease and related dementias later in life, according to a recent study published by Cai et al in JAMA Network Open. Background About 67% of patients with breast...
Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: Effect of Denosumab on Bone Loss
In an Australian single-center trial reported in the Journal of Clinical Oncology, Ramchand et al found that denosumab prevented bone loss vs placebo in premenopausal women with estrogen receptor–positive breast cancer receiving estradiol suppression therapy. Study Details In the double-blind...
Out-of-Pocket Costs From Diagnostic Testing After Prostate Cancer Screening
Prostate-specific antigen (PSA) screening aims to identify patients who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive—and expensive—diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such...
Advanced Classical Hodgkin Lymphoma: PET-Guided BrECADD vs eBEACOPP
As reported in The Lancet by Peter Borchmann, MD, and colleagues, the phase III HD21 trial showed that first-line positron-emission tomography (PET)-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) exhibited greater efficacy and...
UK-Based Survey Finds Cancer Is the Leading Health Concern Among the Public
A new survey conducted in the United Kingdom found two-thirds of the public say they are very or somewhat worried about being told they have cancer—a higher percentage than for any other medical condition, including dementia and having a heart attack—according to polling released today. The...
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...
Novel Immunotherapy Approach in Metastatic Solid Tumors
A novel personalized cellular immunotherapy approach may be effective at treating certain patients with metastatic solid tumors, according to early findings from a recent study published by Parkhurst et al in Nature Medicine. Background Chimeric antigen receptor (CAR) T-cell therapy has already...
Prostate Cancer Detection With AI vs Radiologist Readings of MRI
In a study reported in The Lancet Oncology (PI-CAI), Saha et al found that an artificial intelligence (AI) system’s readings of magnetic resonance imaging (MRI) outperformed study radiologist readings using Prostate Imaging—Reporting and Data System (PI-RADS) version 2.1 in detecting clinically...
Outcomes for BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Therapy
In a single-center study reported in JAMA Network Open, Kerollos Nashat Wanis, MD, PhD, and colleagues found that women with breast cancer and a pathogenic BRCA1/2 variant who underwent breast-conserving therapy had a 71% rate of 10-year bilateral mastectomy–free survival. Study Details The study...
Second-Line ALK-Positive NSCLC With CNS Progression on First-Line Crizotinib
This is Part 3 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the second-line treatment of ALK-positive...
First-Line ALK-Positive NSCLC With CNS Metastases at Baseline and CNS Toxicity
This is Part 2 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the first-line management of ALK-positive...
First-Line ALK-Positive NSCLC With CNS Metastases at Baseline
This is Part 1 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the first-line management of metastatic non–small...
Stage I HER2-Positive Breast Cancer: Long-Term Follow-up of Adjuvant T-DM1
In a 5-year update of the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Tarantino et al found that 1 year of adjuvant ado-trastuzumab emtansine (T-DM1) was associated with “outstanding” long-term outcomes in patients with stage I HER2-positive breast cancer. Study Details In...
Adjuvant Therapeutic Regimens for Gallbladder Cancer
In an Indian phase II trial (GECCOR-GB) reported in JAMA Oncology, Ostwal et al found that both adjuvant gemcitabine/cisplatin (GC) and capecitabine and capecitabine given concurrently with chemoradiation therapy (CCRT) showed activity in patients with resected gallbladder cancer. Study Details In...
Surveillance for Pancreatic Cancer in High-Risk Individuals
In a study reported in JAMA Oncology, Blackford et al found that surveillance of individuals at high risk for pancreatic ductal adenocarcinoma allowed for detection of earlier-stage pancreatic ductal adenocarcinoma—with improved survival—compared with matched pancreatic ductal adenocarcinoma...
40% of Cancer Cases and Almost Half of All Cancer Deaths in the United States Linked to Modifiable Risk Factors
A recent study led by researchers at the American Cancer Society has found that 4 in 10 cancer cases and about half of all cancer deaths in adults aged 30 and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) may be attributed to modifiable risk factors,...
RNAs May Help to Identify Patients With Stage II Colorectal Cancer Who May Benefit From Adjuvant Chemotherapy
Investigators have assessed whether RNAs can be used as a biomarker to predict which patients with stage II colorectal cancer may benefit from postsurgical chemotherapy, according to a recent study published by Korsgaard et al in The American Journal of Pathology. Background Colorectal cancer is...
Predicting Taxane-Induced Peripheral Neuropathy After Breast Cancer Therapy
Researchers have developed a novel tool that may help to predict the risk of experiencing peripheral neuropathy following treatment with taxanes in patients with breast cancer, according to a recent study published by Engvall et al in npj Precision Oncology. The findings may aid physicians in...
Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?
Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...
Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination
In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination was associated with promising recurrence-free survival in patients who had undergone resection and standard-of-care treatments for...
Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death
In a study reported in JAMA Network Open, Plym et al found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the disease. Study Details The cohort study used a combined analysis of...
Predictive Models for Disease Recurrence After Breast-Conserving Surgery for DCIS
In a Canadian study reported in the Journal of Clinical Oncology, Hahn et al evaluated the impact of certain predictive models for local and invasive local recurrence in patients undergoing breast-conserving surgery with or without adjuvant radiotherapy for pure ductal carcinoma in situ (DCIS)....
Certain Patients Diagnosed With 'Benign' Classification of Prostate Cancer May Actually Have High-Risk Disease
Recently, some experts have called for Gleason Grade Group 1 prostate cancer to be reclassified as benign. However, many patients diagnosed with this lowest grade of prostate cancer may have more aggressive disease than their biopsy alone suggests, according to a recent study published by Tilki et...
New Study May Provide Insights Into Immune System Mechanism Shared by Pregnancy and Cancer
By examining the immune system during pregnancy, researchers have uncovered the mechanism that may contribute to oncofetal immune tolerance, according to a recent study published by Yu et al in Cell. Background “In pregnancy, the immune system does not reject the growing fetus, so we know there...
Capivasertib With Fulvestrant for Previously Treated Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
On November 16, 2023, capivasertib (Truqap) was approved for use with fulvestrant for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, following disease progression on at least one endocrine-based...
Having Acute Lymphoblastic Leukemia Took Away My Fear of Death
On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...
Chronic Graft-vs-Host Disease: Clinical Trial Updates
Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...
Breaking the Silence: Addressing Sexual and Reproductive Health in Cancer Care
For patients with cancer and cancer survivors, sexual dysfunction and reproductive health concerns are often the elephant in the exam room—a significant quality-of-life issue that both patients and clinicians struggle to discuss openly and effectively. At the recent NCCN Policy Summit on Sexual and ...
